Please login to the form below

Not currently logged in
Email:
Password:

FDA clears test for Novartis' Zortress

The US Food and Drug Administration has cleared a test that monitors blood levels of Novartis' recently approved immunosuppressant Zortress

The US Food and Drug Administration (FDA) has cleared a test that monitors blood levels of Novartis' recently approved immunosuppressant Zortress (verolimus), a drug that is used to help prevent organ rejection in kidney transplant patients.

Called the QMS Everolimus Immunoassay, the test is made by Thermofisher Scientific. It is the first test to be cleared by the FDA to monitor levels of the drug, which was approved in April 2010 for use in adult kidney transplant patients who are at low-to-moderate immunologic risk.

"Some immunosuppressants are associated with toxic side effects that can injure transplanted kidneys," the FDA explained. "Balancing the levels of immunosuppressants is critical since transplant patients must take these drugs for the rest of their lives."

To secure marketing clearance for the test, Thermofisher compared results obtained from the QMS Everolimus Immunoassay to the results from everolimus reference tests used in the clinical trials of the drug and showed that they were similar.

Novartis' Zortress is an oral tablet designed to help prevent organ rejection and preserve kidney function when used with reduced doses of cyclosporine, an older immunosuppressant with a difficult side effect profile. The new Novartis drug, which works by inhibiting the proliferation of cells that play a key role in transplant rejection, is sold outside the US as Certican.

14th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....